SNORA7A: SNORA7A is an H/ACA box snoRNA that has been identified as a crucial regulator in human umbilical cord mesenchymal stem cell proliferation and self-renewal, which has implications for stem cell therapy [PMC7522514]. It has been found that SNORA7A expression is negatively correlated with cyclin-dependent kinase inhibitor (CDKN1B), adenylyl cyclase (ADCY9), and downstream effector of Rho (ROCK1) [PMC7844330]. SNORA7A, along with SNORA65 and SNORA7B, is highly expressed in tumor samples compared to normal non-tumor matched controls [PMC7862062]. In terms of its function, SNORA7A inhibits osteogenesis by inhibiting H19-induced osteogenic gene expression [PMC7844330]. Other snoRNAs, such as SNORD89 and SNORD42A, have been identified as biomarkers for ovarian cancer and leukemia, respectively [PMC9115109]. Additionally, snoRNAs like SNORA50 and SNORA71A have been shown to act as oncogenes or tumor-suppressive genes in prostate cancer and colorectal cancer [PMC9115109]. In non-small cell lung cancer (NSCLC), snoRNAs like SNORA42 have been found to be activated and regulate cancer development through both p53-dependent and p53-independent pathways [PMC9115109]. Furthermore, increased expression of the H/ACA box protein NOP10 is associated with a poor prognosis in NSCLC patients and its deletion inhibits lung cancer cell growth by dysregulating the expression of snoRNAs such as SNORA65, SNORA7A, and SNORA7B [PMC7862062].